Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

  • Featured Story

    Why the Volcker Rule Is Now 233% Longer

    Adding work
    The 2010 Dodd-Frank law was conceived with the best of intentions - curb the bad behavior of the Too Big to Fail banks that caused the 2008 financial crisis. Front and center was the Volcker Rule, which was to stop the banks' risky and dangerous proprietary trading. Three years later the Volcker Rule has yet to see the light of day,
    but how it's changing is what we really need to worry about...
  • Federal Reserve Chairmen